<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134324">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01353053</url>
  </required_header>
  <id_info>
    <org_study_id>056410</org_study_id>
    <nct_id>NCT01353053</nct_id>
  </id_info>
  <brief_title>Comparison of Two Immunosuppressive Regimens in Kidney Transplant Recipients With Deceased Donors With the Aim of Preventing the Development of Fibrosis / Atrophy of Reducing the Incidence of Cytomegalovirus Infection</brief_title>
  <official_title>Comparison of Two Immunosuppressive Regimens in Kidney Transplant Recipients With Deceased Donors With the Aim of Preventing the Development of Fibrosis / Atrophy of Reducing the Incidence of Cytomegalovirus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this the study is to the assess whether the graft and patient survival, rejection
      rates and renal graft function after the first year will not differ between both study arms.
      The investigators will also the evaluate the reduction in the incidence of cytomegalovirus
      the and improvement of renal function of the everolimus after 1 year.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2010</start_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Disorder of Transplanted Kidney</condition>
  <condition>Cytomegalovirus Infections</condition>
  <arm_group>
    <arm_group_label>Tacrolimus, Everolimus</arm_group_label>
    <description>Immunosuppression is the same for all patients in the study until the period between the 3rd and 5th weeks, when patients will be randomized to initial regimen and remain or be converted to everolimus tacrolimus.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        A randomized study of 82 patients transplanted in first transplant recipients of deceased
        donor and in line for kidney transplantation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with BMI below 30,

          -  first transplants with PRA &lt; 30,

          -  no contraindication for induction Thymoglobuline,

          -  age 18 years or younger than 70 years.

        Exclusion Criteria:

          -  patients with a BMI above 30

          -  retransplantation

          -  patients hypersensitized with PRA &gt; 30

          -  compared with Thymoglobulina indication for induction

          -  age under 18 or over 70 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Israelita Albert Einstein</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucio Requião Moura</last_name>
      <phone>55-11</phone>
      <email>lrequiao@nefro.epm.br</email>
    </contact>
    <investigator>
      <last_name>Alvaro Pacheco-Silva, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <lastchanged_date>May 11, 2011</lastchanged_date>
  <firstreceived_date>May 11, 2011</firstreceived_date>
  <responsible_party>
    <name_title>Alvaro Pacheco e Silva Filho</name_title>
    <organization>Federal University of Sao Paolo</organization>
  </responsible_party>
  <keyword>Immunosuppression</keyword>
  <keyword>Cytomegalovirus</keyword>
  <keyword>Renal Transplant</keyword>
  <keyword>Atrophy/interstitial</keyword>
  <keyword>Conversion of tacrolimus everolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
